Insider buying last 90 days
No open-market insider purchases were filed for ABT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ABT insider filing, plotted on the chart in Gekko.Open ABT in Gekko
NYSE: ABT
Abbott Laboratories (ABT) Stock Analysis & Forecast
$102.61+0.38 (+0.4%)
Close on Sep 18, 2026. Page updated Sep 19, 9:16 pm ET.
Gekko Brief
AI summaryAbbott (ABT) closes at $102.61, up 0.4%, sitting between its 50-day average of $106.02 and 200-day average of $105.20. The GekkoIndex reads 69.4, placing the stock in the Accumulation zone, while the gap to Gekko Fair Value of $121.50 stands at -15.5%. Over the past year the stock is down 23.5%, though the three-month return of 16.1% shows some recent recovery within a wider range between a 52-week low of $81.97 and high of $137.49.
This week's news centers on a legal settlement: Abbott has agreed to pay $384 million, described elsewhere as nearly $385 million, to resolve federal and state claims tied to a 2022 infant formula recall from its Sturgis, Michigan plant, which contributed to a nationwide shortage. New York is set to receive $9.3 million from the settlement. Separately, Abbott declared its 411th consecutive quarterly dividend of 63 cents per share.
Looking ahead, Abbott's next earnings report is due 21 October 2026, 31 days away and outside a typical 20-trading-day holding window; the prior quarter showed adjusted EPS of $1.31 against a $1.28 estimate, with a 12.8% reaction, and guidance was raised to $5.45–$5.60 for the year. Fifteen analysts covering the stock currently rate it buy, with a consensus target of $120.26. Seasonality over the next 20 trading days has averaged -3.7% across 5 years, rising in just 1 of them, a pattern worth noting given no insider, Congress, or unusual options activity appears in the current window.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $102.61200-day averageGekko Fair Value $121.50
Key stats
- Market cap
- $177.5B
- P/E ratio
- 33.1
- Forward P/E
- 16.9
- EPS, TTM
- $3.09
- Revenue, TTM
- $46.59B
- Profit margin
- 11.7%
- Dividend yield
- 2.42%
- Beta
- 0.59
- Volume
- 27.08M avg 8.69M
- 1-year return
- −23.5%
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±4.4%
- 50-day average
- $106.02
- 200-day average
- $105.20
- Next earnings
- Oct 21 before open
- Shares outstanding
- 1.74B
Abbott Laboratories swing-trade checklist
Abbott Laboratories scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $102.61 sits between the 50-day ($106.02) and 200-day ($105.20) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
69.4, Accumulation
Reading 69.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
15.5% below
Price is 15.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 31 days
Next report Oct 21, 2026, 31 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−3.7% on average
From this point in the calendar, the next 20 trading days averaged −3.7% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Abbott Laboratories stock chart and price history
Abbott Laboratories closed at $102.61 on Sep 18, 2026, −23.5% over the past year, inside a 52-week range of $81.97 to $137.49.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −10.3%
- 3 months
- +16.1%
- 6 months
- −4.3%
- 1 year
- −23.5%
The full ABT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ABT in Gekko
Follow Abbott Laboratories through every session
Put ABT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ABT in GekkoFree for 7 days. No credit card required.
About Abbott Laboratories
Abbott Laboratories works across healthcare, researching, making and distributing a broad range of health products worldwide through its own operations and related entities. It is organized into four areas: established pharmaceuticals, diagnostics, nutrition and medical devices. Its pharmaceutical line includes generic medicines for conditions such as digestive disorders, hormone-related issues, cholesterol and blood pressure management, thyroid problems, vertigo, pain and migraine, along with an anti-infective, flu vaccines and treatments that support colon function.
The diagnostics business supplies laboratory systems for immunoassay, chemistry, hematology and transfusion testing, along with molecular platforms that process DNA and RNA and identify infectious agents. It also makes point-of-care devices, testing cartridges, rapid tests for pathogens including HIV, SARS-CoV-2, influenza and RSV, plus tools for cardiometabolic and substance testing, remote monitoring, consumer self-tests and lab automation software. The nutrition segment produces formulas for infants and adults, while the medical devices unit makes cardiovascular products such as rhythm management and structural heart devices, along with diabetes care tools and neuromodulation devices for pain and movement disorders.
Abbott Laboratories was founded in 1888 and is headquartered in North Chicago, Illinois. Its shares are listed on the NYSE under the ticker ABT.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- abbott.com
Abbott Laboratories GekkoIndex: the smart money zone
Abbott Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 69.4, in the Accumulation zone, up 0.8 points over five sessions.
69.4Accumulation
Up 0.8 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 30 | −0.1% | −2.2% | ||
| Accumulation (current zone) | 245 | +0.1% | +0.4% | ||
| Neutral | 356 | 0.0% | +0.1% | ||
| Distribution | 26 | −0.2% | +1.2% | ||
| Selling | 5 | Too few readings yet | |||
Average ABT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ABT price, zone by zone.Track ABT in Gekko
Is Abbott Laboratories stock overvalued? Gekko Fair Value
Abbott Laboratories trades 15.5% below Gekko Fair Value of $121.50, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Abbott Laboratories shares are worth, recalculated every trading day.
$121.50
Gekko Fair Value, Sep 19, 2026
15.5% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ABT in Gekko
Abbott Laboratories insider and Congress trading
No open-market insider purchases were filed for Abbott Laboratories, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ABT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ABT, plotted on the chart in Gekko.Open ABT in Gekko
Buybacks
Abbott Laboratories has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.05B
- As a share of market cap
- 0.59%
- Trailing four quarters
- $1.83B
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ABT.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Abbott Laboratories earnings: next date and track record
Abbott Laboratories reports on Oct 21, 2026, before the open (31 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Oct 21, 2026
Expected before the open, 31 days away
- EPS estimate
- $1.43
- Revenue estimate
- $12.99B
4 of 8reports beat the EPS estimate
±6.2%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 16, 2026 AI summary
- What they said
- Abbott reported Q2 2026 results showing accelerating comparable sales growth of 4.8% and adjusted EPS of $1.31, which exceeded the midpoint of guidance and consensus. Management reaffirmed full-year comparable sales guidance of 6.5%–7.5% and raised adjusted EPS guidance to $5.45–$5.60. Key drivers cited for second-half acceleration include Nutrition, Electrophysiology (EP), Core Lab, and cancer diagnostics (Exact Sciences). Abbott highlighted several near-term and upcoming product and pipeline milestones: completion of patient enrollment in the tectonic coronary IVL pivotal trial, FDA submission for Amulet 360 (left atrial appendage device), CE Mark for Libre Duo (dual glucose-ketone sensor), planned US launches of Amulet 360, Tactiflex Duo PFA catheter, and product rollouts tied to acquisitions (e.g., balloon-expandable TAVR valve, leadless conduction pacing leveraging Avera, mitral replacement valve from Cephea, peripheral IVL from CSI, and a wearable continuous lactate sensor). Financially, adjusted gross margin expanded 100 bps to 58.0%, adjusted R&D was 6.9% of sales, and adjusted SG&A was 28.6% of sales. FX was a modest tailwind in Q2 (+0.8%) and is expected to be +1% for the full year (with roughly -1% in Q3). Management provided Q3 adjusted EPS guidance of $1.38–$1.46. During Q&A management presented a confident tone, addressed concerns about potential procedure-volume deceleration (downplaying material near-term impact), discussed timing uncertainty around CGM reimbursement expansions, confirmed progress integrating Exact Sciences with expected mid-teens contribution for the year, outlined EP launch traction (Bolt/Volt, Tactiflex Duo) and intentions to grow ahead of market, and acknowledged U.S. challenges in Structural Heart with planned personnel and commercial approach changes and expectation of improvement by year-end.
- Guidance
- Reaffirmed full-year comparable sales growth: 6.5%–7.5%; Raised full-year adjusted EPS guidance to $5.45–$5.60; Q3 adjusted EPS guidance: $1.38–$1.46; FX expected to be +1% on full-year sales (approx. -1% impact in Q3).
- Risks flagged
- China VBP headwinds impacting Core Lab and international diagnostics; uncertainty/timing of reimbursement expansion for CGM (Libre Duo) which would materially affect adoption timing; competitive intensity and market-share challenges in U.S. Structural Heart (mitral) requiring commercial/organizational changes; execution and integration risk for recent acquisitions (Exact Sciences integration appears on track); general forward-looking risks noted in opening caution (economic, competitive, regulatory).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 16, 2026 | $1.31 est $1.28 | $12.59B est $12.52B | +12.8% |
| Apr 16, 2026 | $1.15 est $1.15 | — | −4.7% |
| Jan 22, 2026 | $1.50 est $1.49 | $11.46B est $11.80B | −11.0% |
| Oct 15, 2025 | $1.30 est $1.30 | $11.37B est $11.39B | −4.2% |
| Jul 17, 2025 | $1.26 est $1.26 | $11.14B est $11.09B | −6.1% |
| Apr 16, 2025 | $1.09 est $1.07 | $10.36B est $10.41B | +3.8% |
| Jan 22, 2025 | $1.34 est $1.34 | $10.97B est $11.03B | +5.5% |
| Oct 16, 2024 | $1.21 est $1.20 | $10.64B est $10.55B | +1.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Abbott Laboratories stock forecast and analyst price targets
Analysts’ average 12-month price target for Abbott Laboratories is $120.26, +17.2% from the last close, from 15 firms rating the stock in the last 90 days.
$120.26consensus 12-month target, +17.2% from the last close
Now $102.61Avg $120.26
Low $112High $135
Each firm’s latest rating in the last 90 days: 15 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 14 | TD Cowen | $135 | +31.6% |
| Sep 10 | Citi | $125 | +21.8% |
| Sep 8 | Wells Fargo | $112 | +9.2% |
| Sep 1 | J.P. Morgan | — | — |
| Aug 31 | TD Cowen | $135 | +31.6% |
+0.4%average 20-day move after past Accumulation readings
−3.7%average move over the next 20 trading days in the last 5 years
±2.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Abbott Laboratories seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Abbott Laboratories averaged −3.7% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.1% | 0 of 5 |
| Next 10 trading days | −3.8% | 0 of 5 |
| Next 15 trading days | −2.8% | 1 of 5 |
| Next 20 trading days | −3.7% | 1 of 5 |
| Next 30 trading days | −3.4% | 1 of 5 |
For scale, ABT’s typical 20-trading-day move in either direction is about 4.4%.
Abbott Laboratories market cap and key statistics
Abbott Laboratories’s market cap is $177.5B, with a P/E ratio of 33.1 and revenue of $46.59B over the last twelve months.
Valuation
- Market cap
- $177.5B
- P/E ratio
- 33.1
- Forward P/E
- 16.9
- EPS, TTM
- $3.09
- Gekko Fair Value
- $121.50
Trading
- Volume
- 27.08M
- Avg volume, 20 days
- 8.69M
- 52-week high
- $137.49
- 52-week low
- $81.97
- Shares outstanding
- 1.74B
Financials
- Revenue, TTM
- $46.59B
- Profit margin
- 11.7%
- Return on equity
- 10.6%
- Quarterly earnings growth, YoY
- −47.5%
Risk and income
- Beta
- 0.59
- Typical daily move
- ±2.7%
- Typical 20-day move
- ±4.4%
- Dividend yield
- 2.42%
Abbott Laboratories stock news this week
Coverage of Abbott Laboratories this week reads negative: 1 positive, 2 neutral and 17 negative headlines.
- Abbott Laboratories Lobbyists, 2018OpenSecrets, Sep 19
- Abbott Laboratories to pay $384 million over infant formula contamination risk claimsValley News, Sep 18
- NYS to receive $9.3 million in Abbott Laboratories baby formula settlementWGRZ, Sep 18
- Abbott Labs to pay $384M over contaminated infant formula allegationsNewsNation, Sep 18
- Abbott settles safety standards federal suit that started in SturgisSturgis Journal, Sep 18
- Abbott to pay $385 million over Michigan baby formula recall that fueled 2022 shortageYahoo Finance, Sep 18
Abbott Laboratories peers
Abbott Laboratories’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 17.1% above |
| DHRDanaher | Neutral | 1.1% above |
| ISRGIntuitive Surgical | Neutral | 12.3% above |
| MDTMedtronic | Neutral | 24.7% below |
| SYKStryker | Buying | 17.1% below |
| BSXBoston Scientific | Accumulation | 35.9% below |
A peer links to its own page where one exists.
Abbott Laboratories stock FAQ
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is $177.5B at the Sep 18, 2026 close of $102.61, with 1.74B shares outstanding. The shares trade on a P/E ratio of 33.1.
What is the Abbott Laboratories stock forecast?
The consensus analyst 12-month price target for Abbott Laboratories is $120.26, +17.2% from the last close. Of the 15 firms that rated the stock in the last 90 days, 15 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Abbott Laboratories stock overvalued or undervalued?
On Gekko’s estimate Abbott Laboratories is undervalued: the Sep 18, 2026 close of $102.61 is 15.5% below Gekko Fair Value of $121.50. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Abbott Laboratories report earnings next?
Abbott Laboratories is expected to report on Oct 21, 2026, before the market opens (31 days away). Analysts expect earnings of $1.43 per share on revenue of $12.99B. Abbott Laboratories beat the earnings estimate in 4 of its last 8 reports, moving 6.2% on average across the report.
What is Abbott Laboratories’s 52-week high and low?
Abbott Laboratories’s 52-week high is $137.49 and its 52-week low is $81.97; it closed at $102.61 on Sep 18, 2026, −23.5% over the past year.
Is Abbott Laboratories stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Abbott Laboratories the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.